Drug Profile
Research programme: neurodegenerative disorder therapeutics - Biovista
Alternative Names: Combo therapy - BiovistaLatest Information Update: 10 Jan 2023
Price :
$50
*
At a glance
- Originator Biovista
- Class Neuroprotectants
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
Most Recent Events
- 10 Jan 2023 Preclinical trials in Neurodegenerative disorders (Combination therapy) in USA (Biovista pipeline, January 2023)
- 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative disorders (Combination therapy) in USA
- 29 May 2013 Biovista plans proof-of-concept trials for Neurodegenerative disorders in USA